21 Documents disponibles dans cette catégorie
Aim: Buprenorphine is an effective medication for treatment of opioid dependence. An injectable depot formulation of buprenorphine has been developed using biodegradable polymer microcapsule technology. This formulation may offer effective treat[...]
A. DESCHENAU ; A. AL TABCHI ; M. C. NOURY ; L. MICHELETTI ; H. ALI-DIABACTE ; E. VODISLAV ; N. TEXIER ; S. HERVY ; D. TOUZEAU | 2024
Dans Heroin Addiction and Related Clinical Problems (Vol.26, 2024) Article : PériodiqueBackground: In 2019, 177,000 patients suffering from opioid use disorder were treated in France with opioid agonist treatments (59% received buprenorphine). In Europe, CAM2038, a subcutaneous buprenorphine depot formulation, was licensed in 2018[...]
The aim of this study was to profile and compare blood naltrexone and 6-ß-naltrexol levels with time following treatment with two sustained-release naltrexone preparations produced by GoMedical lndustries, Australia at a community heroin treatme[...]
FRANÇAIS : Commentaire de l'article de Sigmon C et Al. publié dans ce numéro d'Addiction (1439-1449)
S. L. WALSH ; S. D. COMER ; M. R. LOFWALL ; B. VINCE ; N. LEVY-COOPERMAN ; D. KELSH ; M. A. COE ; J. D. JONES ; P. A. NUZZO ; F. TIBERG ; B. SHELDON ; S. KIM | 2017
Dans JAMA Psychiatry (Vol.74, n°9, September 2017) Article : PériodiqueImportance: Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may be obviated by a sustained r[...]
FRANÇAIS : Chez15 usagers dépendant des opioïdes on a pratiqué soit un implant de buprénorphine 58 mg soit un placebo. La buprénorphine sous cutanée a supprimé les symptômes de sevrage et a eu des effets agonistes opioïdes. ENGLISH : Aims: Bu[...]
M. REISINGER ; M. REISINGER | 2024
Dans Heroin Addiction and Related Clinical Problems (Vol.26, 2024) Article : PériodiqueVincent Dole described the discovery of methadone treatment for heroin addicts in 1963 as a "therapeutic revolution". Twenty years later, buprenorphine constituted a second therapeutic revolution. Therapeutic safety and the absence of euphoria g[...]
J. E. CARRENO ; C. E. ALVAREZ ; G. I. SAN NARCISO ; M. T. BASCARAN ; DIAZ M. ; J. BOBES | 2003
PériodiqueENGLISH : A report is presented of treatment of 156 patients (male 98%) with opioid dependence (ICD-10 criteria) using a maintenance programme with depot opioid antagonists (naltrexone) as subcutaneous implants, started after an outpatient rap[...]
L. MICHELETTI ; M. C. NOURY | 2023
Dans Courrier des Addictions (Le) (Vol.25, n°1, Janvier-février-mars 2023) Article : PériodiqueFRANÇAIS : La buprénorphine à libération prolongée, en dépôt sous-cutané, est une nouvelle option thérapeutique pour les personnes dépendantes aux opiacés. Entre octobre 2021 et décembre 2022, 42 usagers du CSAPA Bagneux ont pu bénéficier de ce[...]
ENGLISH : Early relapse is common after opiate withdrawal and deprives addicts of important opportunities to develop new, opiate-free cognitive-behavioural habits. The oral opiate antagonist naltrexone (NTX) significantly reduces relapse only [...]
V. D. HOPE ; J. V. PARRY ; F. NCUBE ; M. HICKMAN | 2016
Dans International Journal of Drug Policy (Vol.28, February 2016) Article : PériodiqueBackground: The extent of intentional or accidental subcutaneous and intramuscular injections and the factors associated with these have rarely been studied among people who inject drugs, yet these may play an important role in the acquisition b[...]
SOBEL B. F. X. ; S. C. SIGMON ; S. L. WALSH ; R. E. JOHNSON ; I. A. LIEBSON ; NUWAYSER E. S. ; KERRIGAN J. H. ; G. E. BIGELOW | 2004
PériodiqueENGLISH : Buprenorphine, a partial mu-opioid agonist, has been shown effective for treatment of opioid dependence but also has some abuse potential. A novel formulation of buprenorphine, using a polymer microcapsule depot sustained-release tec[...]
Treatment for opioid use disorder may involve buprenorphine - a drug that can reduce or eliminate withdrawal symptoms and prevent relapse. We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disor[...]
Historique
